Mytesi is an anti-diarrheal drug owned by Napo Pharms Inc. It contains the active ingredient crofelemer and was first authorized for market use on December 31, 2012. Mytesi holds 3 drug patents, one of which has already expired.
The generic versions of Mytesi are expected to be released after October 31, 2031. This is due to the expiration of patent US9585868 titled 'Methods and compositions for treating HIV-associated diarrhea', which holds the latest expiry date among Mytesi's patents.
Mytesi is used for the symptomatic relief of non-infectious diarrhea. It's effectiveness is largely due to its active ingredient, crofelemer, which plays a crucial role in managing diarrhea symptoms.
Mytesi has held 3 drug patents, with the last one due to expire on October 31, 2031. This patent, US9585868, is titled 'Methods and compositions for treating HIV-associated diarrhea'. This event will pave the way for the release of Mytesi generic. Below are the details of the patent: